Controlant | December 16, 2020
Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation.
In addition to the visibility and monitoring arrangements that Controlant is providing to Pfizer to mRNA-based Pfizer-BioNTech COVID-19 vaccine distribution supply chain, the organization is likewise working straightforwardly with the U.S. Government and wellbeing authorities, for example, the Center for Disease Control (CDC), U.S. Division of Health and Human Services (HHS), and stakeholders in Operation Warp Speed, to give nearby observing at U.S. Government-preferred designated vaccination areas to help consistently guarantee coherence during hand-off, actionable communication, and visibility, all through the entirety of the U.S. supply chain journey of the vaccines.
CELL AND GENE THERAPY
EVONETIX LTD | March 02, 2022
EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabling the production of scarless DNA sequences that are directly compatible with downstream processing.
Synthetic biology is expected to impact many industries, but the production of high-fidelity DNA at scale, without the need for post-synthesis error correction, has remained a challenge. Evonetix‘s unique approach re-engineers traditional phosphoramidite synthesis chemistry to use thermal, rather than acidic, control of deprotection reactions. This approach enables parallel synthesis of thousands of sequences on a single chip.
The research was directed by Dr Raquel Sanches-Kuiper, VP of Technology at Evonetix, whose enzyme engineering team has focussed on the development of enzymes that can incorporate Evonetix modified nucleotides efficiently. The programme was completed in collaboration with Dr David Hodgson, Associate Professor of Chemistry at Durham University, whose group was involved in developing the modified nucleotides for enzymatic synthesis in Evonetix silicon arrays.
“We have, for the first time, demonstrated thermally controlled enzymatic DNA synthesis. Our approach brings together thermally controlled synthesis and error detection, allowing for high-throughput assembly of high-fidelity gene-length DNA at scale. Our synthesis platform can now be used with both enzymatic and chemical synthesis, allowing us to smoothly integrate our enzymatic approach as this technology develops. Our unique, on-chip, synthesis and error correction platform will overcome many of the existing challenges in current approaches to de novo gene synthesis.”
Dr Raquel Sanches-Kuiper, VP of Technology at Evonetix
Dr David Hodgson, Associate Professor of Chemistry at Durham University, added: “We have been able to combine our world leading expertise in nucleotide chemistry with the novel Evonetix approach for enzymatic DNA synthesis, enabling cleaner, simpler synthesis reactions that will ultimately allow for scaled production of high-quality synthetic DNA with revolutionary applications across industry and research.”
Simon Rowland, Innovate UK, commented “Engineering Biology was identified in the 2021 UK Innovation Strategy as one of the key technologies that will deliver future economic success in the UK. The rapidly growing synthetic biology market is estimated to reach $40 billion by the mid-2020s. Innovate UK supports businesses and research institutions to drive business investment into R&D and is proud to have supported Evonetix and the development of this game changing innovation in DNA synthesis.”
Gator Bio, Inc. | June 02, 2022
Gator Bio, the next gen Biolayer Interferometry solutions company, has signed an agreement with I&L Biosystems GmbH, a distributor of innovative biomedical technology and products. The agreement will allow Gator Bio to expand rapidly its product offerings into the European Union, a key region for Gator's growth strategy as it begins its global reach.
I&L Biosystems has a history of bringing new and innovative technologies into market — as evidenced by its previous success in commercializing e.g., various multi-analyzer, protein purification devices, SPR instruments, and bioreactors, etc. We look forward to working with the I&L team to bring the Gator platform to users throughout the region, helping meet the demand for therapeutics development and manufacturing."
Dr. Hong Tan, CEO of Gator Bio.
Gator BLI platform and a range of innovative biosensors are an important addition to I&L's portfolio of protein characterization products, and we are very excited about the possibilities the Gator shall give our customers in characterizing antibodies, AAVs and small molecule drugs, Access to this next gen technology is key to the continued enablement of our biopharma and academia research customers across our geographies. We are very excited about helping research and manufacturing community with the novel applications in gene therapy, immune therapy and lipid nano particle development."
Mr. Alexander M. Beljaars, CEO of I&L Biosystems GmbH.
The latest partnership of two companies builds on Gator Bio's commitment to providing high-quality BLI platforms globally, recently demonstrated through a strategic partnership with BMS Korea (Bio Medical Sciences) to provide sales and services to biotherapeutics and gene therapy companies in Republic of Korea.
About Gator Bio, Inc.
Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China.
About I&L Biosystems
I&L Biosystems is a leading distributor of innovative scientific products with the headquarter in Königswinter, Germany. The company was founded in 1991 and has been growing steadily ever since. The focus of I&L is on sales and distribution of high-quality laboratory equipment to customers and researchers in the microbiology, cell biology and biotechnology markets in almost all European countries. High quality of the products, competent advice and fast service are the basis for a long-lasting relationship with our customers and partners in industry, research and development. More than 120 employees ensure that our customers throughout Europe receive excellent support for technical or application-related questions.